Alisol B
Based on 1 publication(s) in Google Scholar
Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a Ki of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.57%
- CAS No.: 18649-93-9
- Formule: C30H48O4
- Masse moléculaire:472.70
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Oxygen Sensing Compound Library
HY-L045
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Terpenoids Library
HY-L056
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Cancer Natural Product Library
HY-L107
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Osteogenesis Compound Library
HY-L131
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Alisol B
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
8.8 μM
Compound: 25
|
Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay
Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay
|
[PMID: 31494470] |
Alisol B (0.5-5 μM; 6 days) dose-dependently inhibits 1α,25(OH)2D3-induced osteoclast formation in co-cultures of mouse bone marrow cells and primary calvarial osteoblasts, with complete inhibition at 5 μM[1].
Alisol B (0.5-5 μM; 10 min) inhibits RANKL-induced JNK phosphorylation in mouse BMMs, and suppresses RANKL-induced activation of NFATc1 and expression of c-Fos, key transcription factors for osteoclastogenesis[1].
Alisol B (1, 5 μM; 48 h) suppresses the pit-forming activity and disrupts actin ring formation of mature mouse osteoclasts on dentin slices[1].
Alisol B (20 μM; 1 h pre-incubation, 24 h co-incubation with Cisplatin (HY-17394)) attenuates cisplatin-induced apoptosis, inflammation, and oxidative stress in HK-2 renal proximal tubule cells via a GSK3β-dependent pathway[2].
Alisol B potently inhibits SERCA1A activity in rabbit skeletal muscle sarcoplasmic reticulum membranes with an IC50 of 27 μM, and inhibits SERCA2B activity in porcine brain microsomes with an IC50 of 53 μM[3].
Alisol B (30 μM; 16-24 h) induces autophagosome formation in MCF-7 cells, as shown by increased GFP-LC3 puncta formation[3].
Alisol B (48 h) induces cytotoxicity across a panel of cancer cell lines with IC50 values ranging from 20.6 μmol/L (HepG2) to 48.7 μM (MDA-MB-231) at 48 h post-treatment[3].
Alisol B (30 μM; 8-48 h) induces time-dependent G1 phase cell cycle arrest in MCF-7 cells, with 93.1% of cells in G1 phase after 48 h of treatment[3].
Alisol B (30 μM; 4-24 h) activates the CaMKK-AMPK-mTOR pathway in MCF-7 cells, as shown by increased AMPKα phosphorylation and reduced p70S6 kinase phosphorylation over time[3].
Alisol B (30 μM; 16 h) induces autophagy and cytotoxicity in MCF-7 cells in an intracellular calcium- and CaMKK-dependent manner[3].
Alisol B (30 μM; 8-24 h) activates the UPR in MCF-7 cells through the PERK and ATF6 signaling pathways, but does not activate the IRE1 pathway[3].
Alisol B (30 μM; 24-48 h) induces late apoptotic cell death in MCF-7 cells, as shown by increased Annexin V+7AAD+ cells and PARP cleavage after 48 h of treatment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 cells expressing GFP-LC3
-
Concentration:30 μM
-
Incubation Time:16 h; 24 h
-
Result:Significantly increased the percentage of cells exhibiting GFP-LC3 puncta, a marker of autophagosome formation.
-
Cell Line:MCF-7 cells
-
Concentration:30 μM
-
Incubation Time:16 h; 24 h
-
Result:Led to detection of numerous double-membraned autophagosomes and autophagic vacuoles containing degraded organelles in treated cells.
-
Cell Line:MCF-7 cells
-
Concentration:30 μM
-
Incubation Time:8 h; 12 h; 16 h; 20 h
-
Result:Increased LC3-II levels over time.
Showed further enhanced LC3-II accumulation when co-treated with lysosomal protease inhibitors, indicating increased autophagosome formation and enhanced autophagic flux.
-
Cell Line:MCF-7 cells
-
Concentration:30 μM
-
Incubation Time:8 h; 16 h; 24 h; 48 h
-
Result:Induced time-dependent accumulation of cells in the G1 phase.
Caused concomitant reductions in S phase and G2-M phase.
-
Cell Line:MCF-7, SK-BR-3, HeLa cells
-
Concentration:30 μM
-
Incubation Time:4 h; 8 h; 16 h; 20 h; 24 h; 48 h
-
Result:Induced time-dependent accumulation of p27 protein in MCF-7, SK-BR-3, and HeLa cells.
Alisol B (15-60 mg/kg; p.o.; daily; 7 days) dose-dependently protects against Cisplatin-induced acute kidney injury in male C57BL/6 wild-type mice by inhibiting sEH activity, and attenuating renal apoptosis, inflammation, and oxidative stress via GSK3β-mediated p53, NF-κB, and Nrf2 signaling pathways[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 wild-type (male, 23-25 g, Cisplatin-induced)[2]
-
Dosage:15 mg/kg; 30 mg/kg; 60 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Reduced Cisplatin-induced elevations in blood urea nitrogen and serum creatinine, and reduced the renal weight/body weight ratio while reversing Cisplatin-induced body weight loss.
Reduced acute tubular necrosis scores.
Reduced the number of TUNEL-positive nuclei, reversed cisplatin-induced increases in cleaved-caspase 3, cleaved-PARP, p53 protein levels, and the Bax/Bcl-2 protein ratio.
Reduced cisplatin-induced increases in ICAM-1 and MCP-1 positive staining in renal sections.
Reduced Cisplatin-induced increases in 4-HNE, 8-OXO, and Grp78 positive staining in renal sections; reduced renal malonyldiadehyde (MDA) levels, and increased renal glutathione (GSH) and superoxide dismutase (SOD) levels.
Upregulated mRNA expression of Nrf2, HO-1, GCLC, GCLM, and NQO-1, downregulated Keap1 mRNA expression, and modulated corresponding protein levels to activate the Nrf2 pathway.
Increased renal levels of 8,9-EET, 11,12-EET, and 14,15-EET.
Chemical Information
-
CAS No. 18649-93-9
-
Appearance Solid
-
Masse moléculaire 472.70
-
Formule C30H48O4
-
Color White to off-white
-
SMILES
C[C@]([C@@]1(C2=C([C@H](C)C[C@@H]([C@]3([H])C(C)(C)O3)O)CC1)C)(CC[C@@]4([H])C5(C)C)[C@]([C@H](C2)O)([H])[C@]4(CCC5=O)C
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
DMSO : 100 mg/mL (211.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.29 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lee JW, et al. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice. Biochem Pharmacol. 2010;80(3):352-361. [Content Brief]
[2]. Zhang J, et al. Direct targeting of sEH with alisol B alleviated the apoptosis, inflammation, and oxidative stress in cisplatin-induced acute kidney injury. Int J Biol Sci. 2023;19(1):294-310. Published 2023 Jan 1. [Content Brief]
[3]. Law BY, et al. Alisol B, a novel inhibitor of the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis. Mol Cancer Ther. 2010;9(3):718-730. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1155 mL | 10.5775 mL | 21.1551 mL | 52.8877 mL |
| 5 mM | 0.4231 mL | 2.1155 mL | 4.2310 mL | 10.5775 mL | |
| 10 mM | 0.2116 mL | 1.0578 mL | 2.1155 mL | 5.2888 mL | |
| 15 mM | 0.1410 mL | 0.7052 mL | 1.4103 mL | 3.5258 mL | |
| 20 mM | 0.1058 mL | 0.5289 mL | 1.0578 mL | 2.6444 mL | |
| 25 mM | 0.0846 mL | 0.4231 mL | 0.8462 mL | 2.1155 mL | |
| 30 mM | 0.0705 mL | 0.3526 mL | 0.7052 mL | 1.7629 mL | |
| 40 mM | 0.0529 mL | 0.2644 mL | 0.5289 mL | 1.3222 mL | |
| 50 mM | 0.0423 mL | 0.2116 mL | 0.4231 mL | 1.0578 mL | |
| 60 mM | 0.0353 mL | 0.1763 mL | 0.3526 mL | 0.8815 mL | |
| 80 mM | 0.0264 mL | 0.1322 mL | 0.2644 mL | 0.6611 mL | |
| 100 mM | 0.0212 mL | 0.1058 mL | 0.2116 mL | 0.5289 mL |
Alisol B Related Classifications
HY-N0805A Related Classifications
Powered by Bioz